Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial

Affiliations

¹ Interdisciplinary Genitourinary Oncology, West-German Cancer Center, University Hospital Essen, Essen, Germany. Electronic address: viktor.gruenwald@uk-essen.de.
² Department of Urology, University Hospital Essen, Essen, Germany.

Comment

Viktor Grünwald et al. Eur Urol. 2019 Apr.

. 2019 Apr;75(4):697-698.

doi: 10.1016/j.eururo.2018.12.018. Epub 2018 Dec 21.

¹ Interdisciplinary Genitourinary Oncology, West-German Cancer Center, University Hospital Essen, Essen, Germany. Electronic address: viktor.gruenwald@uk-essen.de.
² Department of Urology, University Hospital Essen, Essen, Germany.

No abstract available

Comment on

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Choueiri TK, et al. Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9. Lancet Oncol. 2018. PMID: 29530667 Clinical Trial.